Trial · NCT07218809
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809, Phase 3, Recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer. Trials, record NCT07218809. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07218809
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- NCT number
- NCT07218809
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 1,100 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan
- First posted
- 2025-10-20
- Last updated
- 2026-07-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free Survival (PFS) | Up to approximately 5 years | PFS is defined as the time from randomization to radiographic progression as assessed by the Investigator per RECIST v1.1, or death due to any cause. |
| Secondary | Overall survival (OS) | Up to approximately 5 years | OS is defined as the time from randomisation until the date of death due to any cause. |
| Other | Second progression free survival (PFS2) | Up to approximately 5 years | Time from randomization to second progression or death (PFS2) is defined as the time from randomization to the earliest progression event (following the initial progression) subsequent to the first subsequent therapy, or death. |
| Other | Objective response date (ORR) | Up to approximately 5 years | ORR is defined as the proportion of participants who have a complete or partial response, as determined by the investigator, per RECIST v1.1. |
| Other | Duration of response (DoR) | Up to approximately 5 years | DoR is defined as the time from the date of first documented response until the date of documented progression per RECIST v1.1, as assessed by the investigator, or death due to any cause. |
| Other | Health-related Quality of Life (HrQoL) | Up to approximately 5 years | Change from baseline in selected subscales of EORTC QLQ C30; global health status, physical function and EORTC QLQ OV28 hormonal symptoms (EORTC IL). |
| Other | CA-125 Response Rate (CA-125 RR) | Up to approximately 5 years | Proportion of participants achieving CA-125 response per GCIG criteria |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07218809
GET https://conductscience.org/api/trials/v1/NCT07218809/registered